Background: The gut microbiota is altered in patients with chronic kidney disease (CKD), and cardiovascular risk increases with progressive CKD. This study examined the potential link between short chain fatty acids (SCFAs), which are produced by the gut microbiota, and cardiovascular outcomes in patients with CKD. Methods: SCFAs were measured using a targeted liquid chromatography-mass spectrometry platform in baseline plasma samples from 214 patients with CKD enrolled in the Clinical Phenotyping Resource and Biobank Core; 81 patients with coronary artery disease (CAD) and 133 without CAD were randomly assigned to training and validation subsets. The primary outcome was a history of CAD and the secondary outcome was a composite history of cardiovascular disease (CVD) at enrollment. Results: We found significantly higher levels of the SCFA valerate among patients with CAD as compared with patients without CAD in the training set (p < 0.001). The valerate concentrations were also significantly higher among subjects with composite outcomes of CVD compared to those without CVD (p = 0.006). These results were subsequently replicated in the validation set. Logistic regression analysis revealed a strong independent association between plasma valerate levels and CVD in both training and validation sets. When valerate was added to the base clinical model comprising of diabetes, hypertension, urinary protein-creatinine ratio, and estimated glomerular filtration rate, it increased the c-statistics for predicting CVD from 0.68 to 0.79 (p = 0.02) in the training set, an observation which was confirmed in the validation set. -Conclusion: This study provides evidence for alterations in gut-microbiota-derived SCFAs with advancing CKD, demonstrates the association of higher plasma valerate levels with pre-existing CVD, and reveals areas for future exploration of cardiovascular risk in patients with CKD.

Keywords:
Short chain fatty acids, Valerate, Coronary artery disease, Cardiovascular outcomes, Chronic kidney disease
1.
Center for Disease Control and Prevention: National Chronic Kidney Disease Fact Sheet. 2017. http://www.cdc.gov/ckd.
2.
Damsgaard EM, et al: Microalbuminuria as predictor of increased mortality in elderly people. BMJ 1990; 300: 297–300.
3.
Drey N, et al: A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003; 42: 677–684.
4.
Culleton BF, et al: Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214–2219.
5.
Go AS, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
6.
Chronic Kidney Disease Prognosis Consortium, Matsushita K, et al: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073–2081.
7.
Goodrich JK, et al: Human genetics shape the gut microbiome. Cell 2014; 159: 789–799.
8.
Conlon MA, Bird AR: The impact of diet and lifestyle on gut microbiota and human health. Nutrients 2014; 7: 17–44.
9.
Sekirov I, et al: Gut microbiota in health and disease. Physiol Rev 2010; 90: 859–904.
10.
Einheber A, Carter D: The role of the microbial flora in uremia. I. Survival times of germfree, limited-flora, and conventionalized rats after bilateral nephrectomy and fasting. J Exp Med 1966; 123: 239–250.
11.
Wikoff WR, et al: Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009; 106: 3698–3703.
12.
Vaziri ND, et al: Chronic kidney disease alters intestinal microbial flora. Kidney Int 2013; 83: 308–315.
13.
Ramezani A, et al: Role of the gut microbiome in uremia: a potential therapeutic target. Am J Kidney Dis 2016; 67: 483–498.
14.
Satoh M, et al: Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol 2003; 95:e111–e118.
15.
Tang WH, et al: Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015; 116: 448–455.
16.
Lin CJ et al: Meta-analysis of the associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS One 2015; 10:e0132589.
17.
Organ CL, et al: Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail 2016; 9:e002314.
18.
Barreto FC, et al: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551–1558.
19.
Hoverstad T, Midtvedt T: Short-chain fatty acids in germfree mice and rats. J Nutr 1986; 116: 1772–1776.
20.
Trompette A, et al: Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med 2014; 20: 159–166.
21.
Wong J, et al: Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014; 39: 230–237.
22.
Afshinnia F, et al: Impaired beta-oxidation and altered complex lipid fatty acid partitioning with advancing CKD. J Am Soc Nephrol 2018; 29: 295–306.
23.
Afshinnia F, et al: Myeloperoxidase levels and its product 3-chlorotyrosine predict chronic kidney disease severity and associated coronary artery disease. Am J Nephrol 2017; 46: 73–81.
24.
Han J, et al: An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal Chim Acta 2015; 854: 86–94.
25.
Koren O, et al: Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 2011; 108(suppl 1): 4592–4598.
26.
Karlsson FH, et al: Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 2012; 3: 1245.
27.
Tang WH, et al: Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368: 1575–1584.
28.
Gan XT, et al: Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail 2014; 7: 491–499.
29.
Lam V, et al: Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012; 26: 1727–1735.
30.
Wang Z, et al: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57.
31.
Ramezani A, Raj DS: The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 2014; 25: 657–670.
32.
Jiang S, et al: A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression. Antonie Van Leeuwenhoek 2016; 109: 1389–1396.
33.
Le Poul E, et al: Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 2003; 278: 25481–25489.
34.
Pluznick JL, et al: Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A 2013; 110: 4410–4415.
35.
Gao Z, et al: Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509–1517.
36.
Mirmonsef P, et al: Short-chain fatty acids induce pro-inflammatory cytokine production alone and in combination with toll-like receptor ligands. Am J Reprod Immunol 2012; 67: 391–400.
37.
Vinolo MA, et al: SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS One 2011; 6:e21205.
38.
Vieira AT, et al: A role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout. Arthritis Rheumatol 2015; 67: 1646–1656.
39.
Bolognini D, et al: The pharmacology and function of receptors for short-chain fatty acids. Mol Pharmacol 2016; 89: 388–398.
40.
Ge H, et al: Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008; 149: 4519–4526.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.